Research and develop protein kinase inhibitors for human and veterinary medicine. Conduct clinical trials to evaluate the safety and efficacy of its drug candidates. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 8% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 60.3× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $1.4M a year; the problem isn’t sales — it’s costs running above that number.
There is $11.8M in the vault; even if every debt were paid off, $6.9M would remain.
A loss of $1.8M against $1.4M in annual sales.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Sales are going backwards, not just slowing. Council score: 4/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.